CZ300368B6 - Zpusob výroby rapamycinového derivátu - Google Patents

Zpusob výroby rapamycinového derivátu Download PDF

Info

Publication number
CZ300368B6
CZ300368B6 CZ20021136A CZ20021136A CZ300368B6 CZ 300368 B6 CZ300368 B6 CZ 300368B6 CZ 20021136 A CZ20021136 A CZ 20021136A CZ 20021136 A CZ20021136 A CZ 20021136A CZ 300368 B6 CZ300368 B6 CZ 300368B6
Authority
CZ
Czechia
Prior art keywords
acid
rapamycin
process according
ether
alkyl
Prior art date
Application number
CZ20021136A
Other languages
Czech (cs)
English (en)
Other versions
CZ20021136A3 (cs
Inventor
Shaw@Chia-Cheng
Hamilton Sellstedt@John
Noureldin@Razzak
Karen Cheal@Gloria
Fortier@Genevieve
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of CZ20021136A3 publication Critical patent/CZ20021136A3/cs
Publication of CZ300368B6 publication Critical patent/CZ300368B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ20021136A 1999-09-29 2000-09-27 Zpusob výroby rapamycinového derivátu CZ300368B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40883099A 1999-09-29 1999-09-29

Publications (2)

Publication Number Publication Date
CZ20021136A3 CZ20021136A3 (cs) 2002-06-12
CZ300368B6 true CZ300368B6 (cs) 2009-05-06

Family

ID=23617953

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20021136A CZ300368B6 (cs) 1999-09-29 2000-09-27 Zpusob výroby rapamycinového derivátu

Country Status (24)

Country Link
EP (1) EP1216251B1 (enExample)
JP (1) JP4289813B2 (enExample)
KR (1) KR100754236B1 (enExample)
CN (1) CN1176925C (enExample)
AR (1) AR029181A1 (enExample)
AT (1) ATE233269T1 (enExample)
AU (1) AU782234B2 (enExample)
BR (1) BR0014433A (enExample)
CA (1) CA2385461C (enExample)
CZ (1) CZ300368B6 (enExample)
DE (1) DE60001510T2 (enExample)
DK (1) DK1216251T3 (enExample)
EA (1) EA004331B1 (enExample)
ES (1) ES2189768T3 (enExample)
HK (1) HK1044774B (enExample)
HU (1) HUP0202609A3 (enExample)
IL (2) IL148542A0 (enExample)
MX (1) MXPA02003243A (enExample)
NO (1) NO20021360L (enExample)
NZ (1) NZ517644A (enExample)
PL (1) PL200899B1 (enExample)
TW (1) TWI256395B (enExample)
WO (1) WO2001023395A2 (enExample)
ZA (1) ZA200201918B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
EP1660081A1 (en) 2003-09-03 2006-05-31 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
KR20070015544A (ko) * 2004-04-14 2007-02-05 와이어쓰 라파마이신 42-에스테르 유도체의 위치특이성 합성
EP1751168A1 (en) 2004-04-14 2007-02-14 Wyeth Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
TW200616633A (en) 2004-08-10 2006-06-01 Wyeth Corp CCI-779 derivatives and methods of making same
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
JP2008530090A (ja) 2005-02-09 2008-08-07 ワイス Ｃｃｉ−７７９多形及びその使用
EP3488866A1 (en) 2005-11-04 2019-05-29 Wyeth LLC Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
ES2531322T3 (es) 2008-06-17 2015-03-13 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
CN101676291B (zh) 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
AU2011210227A1 (en) * 2010-01-28 2012-08-30 Fresenius Kabi Oncology Ltd. Process for the preparation of Temsirolimus and its intermediates
CN102020662B (zh) 2011-01-07 2013-02-13 天津市炜杰科技有限公司 一种驮瑞塞尔制备方法
RU2603261C2 (ru) * 2011-04-01 2016-11-27 Сандоз Аг Региоселективное ацилирование рапамицина в положении с-42
CN103421023B (zh) * 2013-07-30 2015-09-23 福建省微生物研究所 一种替西罗莫司的合成工艺
CN104086564B (zh) * 2014-07-30 2019-02-05 江苏奥赛康药业股份有限公司 一种高纯度坦罗莫司的制备方法
CN106146536B (zh) * 2015-04-25 2019-07-26 山东新时代药业有限公司 一种依维莫司的制备方法
JP6942141B2 (ja) * 2016-03-14 2021-09-29 ウイスコンシン アラムニ リサーチ ファンデーション 抗がん効能を高めたオリゴ乳酸複合体及びミセル
CN107561170B (zh) * 2016-07-02 2021-07-30 山东新时代药业有限公司 一种坦西莫司中间体的分析检测方法
CN108948045A (zh) * 2017-05-20 2018-12-07 鲁南制药集团股份有限公司 一种替西罗莫司的制备方法
CN108948046B (zh) * 2017-05-20 2020-11-10 鲁南制药集团股份有限公司 一种替西罗莫司的中间体及其制备方法
CN109206441B (zh) * 2017-06-30 2022-05-20 正大天晴药业集团股份有限公司 一种依维莫司的纯化方法
CN109776570A (zh) * 2017-11-14 2019-05-21 上海医药工业研究院 一种依维莫司中间体、其制备方法及其应用
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
CN109369679A (zh) * 2018-12-24 2019-02-22 江苏卓和药业有限公司 一种雷帕霉素的精制方法
CN109851626B (zh) * 2019-01-08 2021-11-02 扬子江药业集团四川海蓉药业有限公司 一种替西罗莫司的分离纯化方法
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
CN113372359A (zh) * 2020-03-10 2021-09-10 鲁南制药集团股份有限公司 一种坦西莫司的制备方法
CN114106014B (zh) * 2020-08-27 2024-03-15 鲁南制药集团股份有限公司 一种依维莫司的制备方法
CN115028658A (zh) * 2022-07-06 2022-09-09 国药集团川抗制药有限公司 雷帕霉素硅醇酯及其制备方法和应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS97392A3 (en) * 1991-04-01 1992-12-16 American Home Prod Rapamycin silyl ethers
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS97392A3 (en) * 1991-04-01 1992-12-16 American Home Prod Rapamycin silyl ethers
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters

Also Published As

Publication number Publication date
PL354461A1 (en) 2004-01-12
WO2001023395A3 (en) 2001-10-25
ATE233269T1 (de) 2003-03-15
ZA200201918B (en) 2003-08-27
NO20021360D0 (no) 2002-03-19
TWI256395B (en) 2006-06-11
AU782234B2 (en) 2005-07-14
MXPA02003243A (es) 2002-09-30
EA004331B1 (ru) 2004-04-29
HUP0202609A2 (hu) 2002-12-28
HK1044774A1 (en) 2002-11-01
CN1176925C (zh) 2004-11-24
EP1216251A2 (en) 2002-06-26
WO2001023395A2 (en) 2001-04-05
ES2189768T3 (es) 2003-07-16
DE60001510T2 (de) 2003-10-02
KR100754236B1 (ko) 2007-09-03
EA200200412A1 (ru) 2002-10-31
JP4289813B2 (ja) 2009-07-01
CZ20021136A3 (cs) 2002-06-12
BR0014433A (pt) 2002-06-11
AU7718200A (en) 2001-04-30
DE60001510D1 (de) 2003-04-03
NO20021360L (no) 2002-03-19
PL200899B1 (pl) 2009-02-27
HUP0202609A3 (en) 2004-11-29
CA2385461C (en) 2009-03-17
KR20020029796A (ko) 2002-04-19
NZ517644A (en) 2003-09-26
CN1402731A (zh) 2003-03-12
IL148542A (en) 2006-08-20
DK1216251T3 (da) 2003-06-16
CA2385461A1 (en) 2001-04-05
IL148542A0 (en) 2002-09-12
AR029181A1 (es) 2003-06-18
JP2003510329A (ja) 2003-03-18
HK1044774B (en) 2003-05-30
EP1216251B1 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
CA2385461C (en) Regioselective synthesis of rapamycin derivatives
US6277983B1 (en) Regioselective synthesis of rapamycin derivatives
US5120842A (en) Silyl ethers of rapamycin
EP1658295B1 (en) Regioselective synthesis of cci-779
CZ284567B6 (cs) Rapamycinové hydroxyestery, způsob jejich přípravy a farmaceutické přípravky, které je obsahují
JP5117390B2 (ja) メイタンシノールの調製法
CA2564811A1 (en) Proline cci-779 (proline-rapamycin 42-ester with 2,2-bis (hydroxymethyl) propionic acid) and two-step enzymatic synthesis of proline cci-779 and cci-779 using microbial lipase
WO1998009972A1 (en) Rapamycin derivatives with unnatural stereochemistries
JP2003510329A5 (enExample)
SG186823A1 (en) Preparation of tesetaxel and related compounds and corresponding synthesis intermediate

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20100927